Optimization of the aerosolization properties of an inhalation dry powder based on selection of excipients

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 70, Issue 3, 2008, Pages 839-844

  Minne, Antoine ^a   Boireau, Hélène ^a   Horta, Maria Joao ^a   Vanbever, Rita ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Aerosolization performance; Excipients; Fine particle fraction; Inhalation dry powders; Particle aggregation; Tap density

Indexed keywords

ALANINE; AMINO ACID DERIVATIVE; DIPALMITOYLPHOSPHATIDYLCHOLINE; EXCIPIENT; GLYCINE; ISOLEUCINE; LEUCINE; TREHALOSE;

AEROSOL; ARTICLE; DRUG FORMULATION; DRY POWDER; INHALER; LASER DIFFRACTION; PARTICLE SIZE; SPRAY DRYING;

1,2-DIPALMITOYLPHOSPHATIDYLCHOLINE; ADMINISTRATION, INHALATION; AEROSOLS; AMINO ACIDS; CHEMISTRY, PHARMACEUTICAL; DRUG COMPOUNDING; EXCIPIENTS; HUMIDITY; HYDROPHOBICITY; PARTICLE SIZE; POWDERS; SURFACE PROPERTIES; TECHNOLOGY, PHARMACEUTICAL; TREHALOSE;

EID: 54949157652     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2008.06.013     Document Type: Article

References (28)

1. Hickey A.J. Pharmaceutical Inhalation Aerosol Technology (2004), Marcel Dekker, New York
2. Kling J. Inhaled insulin's last gasp?. Nat. Biotechnol. 26 (2008) 479-480
3. Armer T.A., Shrewsbury S.B., Newman S.P., Pitcairn G., and Ramadan N. Aerosol delivery of ergotamine tartrate via a breath-synchronized plume-control inhaler in humans. Curr. Med. Res. Opin. 23 (2007) 3177-3187
4. Frijlink H.W., and de Boer A.H. Trends in the technology-driven development of new inhalation devices. Drug Discov. Today: Technol. 2 (2005) 47-57
5. A.R. Clark, Pulmonary delivery technology: recent advances and potential for the new millennium, in: Marcel Dekker, Pharmaceutical inhalation aerosol technology, New York, USA, 2004, pp. 571-591.
6. Hollander P.A. Evolution of a pulmonary insulin delivery system (Exubera) for patients with diabetes. Med. Gen. Med. 9 (2007) 45
7. Seville P.C., Li H.Y., and Learoyd T. Spray-dried powders for pulmonary drug delivery. Crit. Rev. Ther. Drug 24 (2007) 307-360
8. Vanbever R., Mintzes J.D., Wang J., Nice J., Chen D., Batycky R., Langer R., and Edwards D.A. Formulation and physical characterization of large porous particles for inhalation. Pharm. Res. 16 (1999) 1735-1742
9. Bosquillon C., Lombry C., Preat V., and Vanbever R. Influence of formulation excipients and physical characteristics of inhalation dry powders on their aerosolization performance. J. Control. Release 70 (2001) 329-339
10. Codrons V., Vanderbist F., Ucakar B., Preat V., and Vanbever R. Impact of formulation and methods of pulmonary delivery on absorption of parathyroid hormone (1-34) from rat lungs. J. Pharm. Sci. 93 (2004) 1241-1252
11. Steckel H., and Bolzen N. Alternative sugars as potential carriers for dry powder inhalations. Int. J. Pharm. 270 (2004) 297-306
12. Seville P.C., Learoyd T.P., Li H.Y., Williamson I.J., and Birchall J.C. Amino acid-modified spray dried powders with enhanced aerosolisation properties for pulmonary drug delivery. Powder Technol. 178 (2007) 40-50
13. Lechuga-Ballesteros D., Charan C., Stults C.L.M., Stevenson C.L., Miller D.P., Vehring R., Tep V., and Kuo M.C. Trileucine improves aerosol performance and stability of spray-dried powders for inhalation. J. Pharm. Sci. 97 (2008) 287-302
14. R.P. Batycky, M.M. Lipp, R.W. Niven, Use of simple amino acids to form porous particles, US patent 7,252,840 (2004).
15. Arakawa T., Tsumoto K., Kita Y., Chang B., and Ejima D. Biotechnology applications of amino acids in protein purification and formulations. Amino Acids 33 (2007) 587-605
16. Andya J.D., Maa Y.F., Costantino H.R., guyen P.A.N., Dasovich N., Sweeney T.D., Hsu C.C., and Shire S.J. The effect of formulation excipients on protein stability and aerosol performance of spray-dried powders of a recombinant humanized anti-IgE monoclonal antibody. Pharm. Res. 16 (1999) 350-358
17. Bosquillon C., Rouxhet P.G., Ahimou F., Simon D., Culot C., Preat V., and Vanbever R. Aerosolization properties, surface composition and physical state of spray-dried protein powders. J. Control. Release 99 (2004) 357-367
18. Bosquillon C., Preat V., and Vanbever R. Pulmonary delivery of growth hormone using dry powders and visualization of its local fate in rats. J. Control. Release 96 (2004) 233-244
19. Rubin B.K. Therapeutic aerosols and airway secretions. J. Aerosol Med. 9 (1996) 123-130
20. Bosquillon C., Lombry C., Preat V., and Vanbever R. Comparison of particle sizing techniques in the case of inhalation dry powders. J. Pharm. Sci. 90 (2001) 2032-2041
21. Méthodes de pharmacotechnie, in European Pharmacopoeia, third ed., Strabsourg (1996), pp. 141-142.
22. Hinds W.C. Aerosol Technology: Properties, Behavior and Measurement of Airborne Particles (1999), John Wiley & Sons, New York
23. Préparations pour inhalation: évaluation aérodynamique des particules fines-Dose des particules fines et distribution granulométrique des particules, European Pharmacopoeia, Addendum, Strasbourg, 2002, pp. 225-237.
24. Srichana T., Martin G.P., and Marriott C. Dry powder inhalers: the influence of device resistance and powder formulation on drug and lactose deposition in vitro. Eur. J. Pharm. Sci. 7 (1998) 73-80
25. Louey M.D., Razia S., and Stewart P.J. Influence of physico-chemical carrier properties on the in vitro aerosol deposition from interactive mixtures. Int. J. Pharm. 252 (2003) 87-98
26. Adi H., Traini D., Chan H._K., and Young P.M. The influence of drug morphology on the aerosolization efficiency of dry powder inhaler formulations. J. Pharm. Sci. 97 (2008) 2780-2787
27. Tierney K.J., Block D.E., and Longo M.L. Elasticity and phase behavior of DPPC membrane modulated by cholesterol, ergosterol, and ethanol. Biophys. J. 89 (2005) 2481-2493
28. Evora C., Soriano I., Rogers R.A., Shakesheff K.N., Hanes J., and Langer R. Relating the phagocytosis of microparticles by alveolar macrophages to surface chemistry: the effect of 1,2-dipalmitoylphosphatidylcholine. J. Control. Release 51 (1998) 143-152